A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
BeOne Medicines
62 trials monitored
See 8 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
DLBCL
706 trials monitored
See 46 trials at risk
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in adults with DLBCL and other aggressive B-cell malignancies
Trial Details
NCT Number NCT07881211
Lead Sponsor BeOne Medicines
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov